Pacific Biosciences is transitioning to a recurring revenue model as consumables reach a record 55% of Q3 revenue, driving ...

Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP ...

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million ...

PacBio reported Q1 2025 revenue of $37.2 million, a decrease from $38.8 million in Q1 2024, amid restructuring efforts. PacBio reported its financial results for the first quarter of 2025, revealing a ...

PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year ...

MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, ...

Gross profit for the first quarter of 2024 was $11.3 million, representing a 16% increase compared with $9.8 million for the first quarter of 2023 and a gross margin of 29% in the first quarter of ...